Increased class Ib antigen display on TAP-2 mutant cells by a mitochondrial function inhibitor

Area of Science:

• Immunology
• Cell Biology
• Molecular Biology

Background:

• Class I histocompatibility antigen (MHC) display is crucial for immune surveillance.
• The RMA-S cell line exhibits defective MHC class I antigen presentation due to a mutation in the Tap-2 gene.
• This defect impairs the cell's ability to present peptides to cytotoxic T lymphocytes (CTLs).

Purpose of the Study:

• To investigate the effect of mitochondrial function on antigen presentation in the RMA-S cell line.
• To determine if inhibiting mitochondrial ATPase with oligomycin can restore CTL recognition of specific MHC class I antigens.

Main Methods:

• Utilized the RMA-S mutant cell line with a defective Tap-2 gene.
• Incubated RMA-S cells with oligomycin, an inhibitor of mitochondrial ATPase.
• Assessed cell lysis by specific cytotoxic T lymphocytes (CTLs) targeting H2-M3 and Qa-1b antigens.
• Compared results with normal RMA cells and cells treated with other mitochondrial inhibitors.

Main Results:

• Oligomycin treatment significantly increased lysis of RMA-S cells by H2-M3-specific CTLs.
• Lysis by Qa-1b-specific CTLs was restored in oligomycin-treated RMA-S cells.
• Oligomycin did not affect normal MHC class I display on RMA cells.
• Other mitochondrial inhibitors did not enhance CTL lysis, and allogeneic CTL lysis was inconsistently affected.

Conclusions:

• Mitochondrial ATPase inhibition by oligomycin can restore the presentation of certain MHC class I antigens in cells with defective peptide transport.
• This suggests a specific role for mitochondrial function, beyond general cellular ATP levels, in the MHC class I antigen processing and presentation pathway.
• The findings provide insights into the complex interplay between cellular metabolism and immune recognition.